{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:48:22Z","timestamp":1793915302752,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00259-026-07974-4","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:32:20Z","timestamp":1780471940000},"page":"6594-6604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is there a role for early SSTR-targeting PRRT in GEP-NET?"],"prefix":"10.1007","volume":"53","author":[{"given":"Giorgia","family":"Ricciardello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Celesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Iagaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Arco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Curatolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Auditore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Piscopo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Shariftabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Lucio","family":"Vinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Minutoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2842-0301","authenticated-orcid":false,"given":"Riccardo","family":"Laudicella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"7974_CR1","doi-asserted-by":"publisher","first-page":"e13425","DOI":"10.1111\/jne.13425","volume":"37","author":"R Kashyap","year":"2025","unstructured":"Kashyap R, Raja S, Adusumilli A, Gopireddy MMR, Loveday BPT, Alipour R, Kong G. Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: A scoping review. J Neuroendocrinol. 2025;37:e13425. https:\/\/doi.org\/10.1111\/jne.13425.","journal-title":"J Neuroendocrinol"},{"key":"7974_CR2","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3390\/ijms24021418","volume":"24","author":"AA Gheorghi\u0219an-G\u0103l\u0103\u021beanu","year":"2023","unstructured":"Gheorghi\u0219an-G\u0103l\u0103\u021beanu AA, Ilie\u0219iu A, Lambrescu IM, \u021a\u0103poi DA. The complex histopathological and immunohistochemical spectrum of neuroendocrine tumors-an overview of the latest classifications. Int J Mol Sci. 2023;24:1418.","journal-title":"Int J Mol Sci"},{"key":"7974_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1159\/000516015","volume":"11","author":"LM Raymond","year":"2021","unstructured":"Raymond LM, Korzun T, Kardosh A, Kolbeck KJ, Pommier R, Mittra ES. The state of peptide receptor radionuclide therapy and its sequencing among current therapeutic options for gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2021;11:1086\u201398.","journal-title":"Neuroendocrinology"},{"key":"7974_CR4","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti. A. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844\u201360.","journal-title":"Ann Oncol"},{"key":"7974_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O\u2019Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, \u00d6berg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"7974_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","volume":"12","author":"U Hennrich","year":"2019","unstructured":"Hennrich U, Kopka K. Lutathera\u00ae: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals. 2019;12:114.","journal-title":"Pharmaceuticals"},{"key":"7974_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s00259-013-2454-3","volume":"41","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, H\u00f6rsch D, O\u2019Dorisio MS, O\u2019Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;41:584.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7974_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40336-025-00679-y","volume":"13","author":"R Laudicella","year":"2025","unstructured":"Laudicella R, Albano D, Bauckneht M, Urso L, De Rimini ML, Grana CM, Baldari S, Versari A, Filice A, Bartolomei M, Maccauro M. Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET). Clin Transl Imaging. 2025;13:105\u201320.","journal-title":"Clin Transl Imaging"},{"key":"7974_CR9","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garc\u00eda-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317.","journal-title":"Lancet"},{"key":"7974_CR10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"7974_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00423-009-0520-x","volume":"395","author":"O Stoeltzing","year":"2010","unstructured":"Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J, Schlitt HJ. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg. 2010;395:185\u201392.","journal-title":"Langenbecks Arch Surg"},{"key":"7974_CR12","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.3748\/wjg.15.5867","volume":"15","author":"D Kaemmerer","year":"2009","unstructured":"Kaemmerer D, Prasad V, Daffner W, H\u00f6rsch D, Kl\u00f6ppel G, Hommann M, Baum RP. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol. 2009;15:5867\u201370.","journal-title":"World J Gastroenterol"},{"key":"7974_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/RLU.0b013e318238f111","volume":"37","author":"S Ezziddin","year":"2012","unstructured":"Ezziddin S, Lauschke H, Schaefers M, Meyer C, van Essen M, Biersack HJ, Kwekkeboom DJ, Ahmadzadehfar H. Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. Clin Nucl Med. 2012;37:102\u20134.","journal-title":"Clin Nucl Med"},{"key":"7974_CR14","first-page":"137","volume":"15","author":"A Sowa-Staszczak","year":"2012","unstructured":"Sowa-Staszczak A, Pach D, Stefa\u0144ska A, Szybi\u0144ski P, Kulig J, Tomaszewska R, Chrzan R, Hubalewska-Dydejczyk A. Case report of a patient with initially inoperable well-differentiated midgut neuroendocrine tumor (WDNT)-PRRT and long-acting somatostatin analogs as the neoadjuvant therapy. Nucl Med Rev Cent East Eur. 2012;15:137\u20139.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"7974_CR15","doi-asserted-by":"crossref","unstructured":"Frilling A, Giele H, Vrakas G, Reddy S, Macedo R, Al-Nahhas A, Wasan H, Clift AK, Gondolesi GE, Vianna RM, Friend P, Vaidya A. Modified liver-free multivisceral transplantation for a metastatic small bowel neuroendocrine tumor: a case report. Transplant Proc. 2015;47:858\u2009\u2013\u200962.","DOI":"10.1016\/j.transproceed.2015.01.007"},{"key":"7974_CR16","first-page":"18","volume":"2018","author":"TN da Silva","year":"2018","unstructured":"da Silva TN, van Velthuysen MLF, van Eijck CHJ, Teunissen JJ, Hofland J, de Herder WW. Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. Endocrinol Diabetes Metab Case Rep. 2018;2018:18\u20130015.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"7974_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12020-020-02341-1","volume":"70","author":"C Chiapponi","year":"2020","unstructured":"Chiapponi C, L\u00fcrssen N, Cremer B, Wahba R, Drebber U, Faust M, Schmidt M, Stippel DL. Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experience. Endocrine. 2020;70:187\u201393.","journal-title":"Endocrine"},{"key":"7974_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s12020-021-02662-9","volume":"73","author":"I Zanata","year":"2021","unstructured":"Zanata I, Ambrosio MR, Zatelli MC. Neoadjuvant PRRT for advanced pNEN: an unusual highlander. Endocrine. 2021;73:493\u20135.","journal-title":"Endocrine"},{"key":"7974_CR19","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00259-011-1835-8","volume":"38","author":"A Sowa-Staszczak","year":"2011","unstructured":"Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefa\u0144ska A, Tomaszuk M, Ko\u0142odziej M, Miko\u0142ajczak R, Pawlak D, Hubalewska-Dydejczyk A. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38:1669\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7974_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejso.2011.08.129","volume":"38","author":"TW Barber","year":"2012","unstructured":"Barber TW, Hofman MS, Thomson BN, Hicks RJ. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012;38:64\u201371.","journal-title":"Eur J Surg Oncol"},{"key":"7974_CR21","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2967\/jnumed.115.158899","volume":"56","author":"EI van Vliet","year":"2015","unstructured":"van Vliet EI, van Eijck CH, de Krijger RR, van Nieveen EJ, Teunissen JJ, Kam BL, de Herder WW, Feelders RA, Bonsing BA, Brabander T, Krenning EP, Kwekkeboom DJ. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate. J Nucl Med. 2015;56:1647\u201353.","journal-title":"J Nucl Med"},{"key":"7974_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.surg.2017.11.007","volume":"163","author":"S Partelli","year":"2018","unstructured":"Partelli S, Bertani E, Bartolomei M, Perali C, Muffatti F, Grana CM, Schiavo Lena M, Doglioni C, Crippa S, Fazio N, Zamboni G, Falconi M. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2018;163:761\u20137.","journal-title":"Surgery"},{"key":"7974_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12022-020-09623-4","volume":"31","author":"M Schiavo Lena","year":"2020","unstructured":"Schiavo Lena M, Partelli S, Castelli P, Andreasi V, Smart CE, Pisa E, Bartolomei M, Bertani E, Zamboni G, Falconi M, Doglioni C. Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT). Endoc pathol. 2020;31:119\u201331.","journal-title":"Endoc pathol"},{"key":"7974_CR24","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.2967\/jnumed.120.258772","volume":"62","author":"RV Parghane","year":"2021","unstructured":"Parghane RV, Bhandare M, Chaudhari V, Ostwal V, Ramaswamy A, Talole S, Shrikhande SV, Basu S. Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2021;62:1558\u201363.","journal-title":"J Nucl Med"},{"key":"7974_CR25","doi-asserted-by":"publisher","first-page":"687925","DOI":"10.3389\/fonc.2021.687925","volume":"11","author":"M Opali\u0144ska","year":"2021","unstructured":"Opali\u0144ska M, Sowa-Staszczak A, Grochowska A, Olearska H, Hubalewska-Dydejczyk A. Value of peptide receptor radionuclide therapy as neoadjuvant treatment in the management of primary inoperable neuroendocrine tumors. Front Oncol. 2021;11:687925.","journal-title":"Front Oncol"},{"key":"7974_CR26","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1007\/s00259-022-05734-8","volume":"49","author":"NS Minczeles","year":"2022","unstructured":"Minczeles NS, van Eijck CHJ, van Gils MJ, van Velthuysen MF, van Nieveen EJM, Feelders RA, de Herder WW, Brabander T, Hofland J. Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. Eur J Nucl Med Mol Imaging. 2022;49:3203\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7974_CR27","doi-asserted-by":"publisher","first-page":"znae178","DOI":"10.1093\/bjs\/znae178","volume":"111","author":"S Partelli","year":"2024","unstructured":"Partelli S, Landoni L, Bartolomei M, Zerbi A, Grana CM, Boggi U, Butturini G, Casadei R, Salvia R, Falconi M. Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. Br J Surg. 2024;111:znae178.","journal-title":"Br J Surg"},{"key":"7974_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4103\/ijnm.IJNM_58_20","volume":"35","author":"KK Kamaleshwaran","year":"2020","unstructured":"Kamaleshwaran KK, Suneelkumar M, Madhusairam R, Radhakrishnan EK, Arunpandiyan S, Arnold VJ. Whole-body and single-photon emission computed tomography\/computed tomography postpeptide receptor alpha radionuclide therapy images of actinium 225-Tetraazacyclododecanetetraacetic Acid-octreotide as a primary modality of treatment in a patient with advanced rectal neuroendocrine tumor with metastases. Indian J Nucl Med. 2020;35:226\u20138.","journal-title":"Indian J Nucl Med"},{"key":"7974_CR29","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1097\/RLU.0000000000003823","volume":"47","author":"S Satapathy","year":"2022","unstructured":"Satapathy S, Sood A, Das CK, Kavanal AJ, Mittal BR. Alpha before beta: exceptional response to first-line 225Ac-DOTATATE in a patient of metastatic neuroendocrine tumor with extensive skeletal involvement. Clin Nucl Med. 2022;47:e156\u20137.","journal-title":"Clin Nucl Med"},{"key":"7974_CR30","doi-asserted-by":"publisher","first-page":"e41853","DOI":"10.1097\/MD.0000000000041853","volume":"104","author":"C von Hessert-Vaudoncourt","year":"2025","unstructured":"von Hessert-Vaudoncourt C, Maasberg S, Begum N, Rinke A, P\u00f6ppel T, Sipos B, Grohe C, Fottner C, Stintzing S, Grabowski P, German NET, Registry. Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study. Med (Baltim). 2025;104:e41853.","journal-title":"Med (Baltim)"},{"key":"7974_CR31","doi-asserted-by":"publisher","first-page":"105795","DOI":"10.1016\/j.ejmp.2026.105795","volume":"145","author":"A Capotosti","year":"2026","unstructured":"Capotosti A, Dav\u00ec V, Laudicella R, Surgo A, Ciliberti MP, Carbonara R, Di Guglielmo FC, Bonaparte I, Moretti R, Cusumano D, Fiorentino A. Radiotherapy and nuclear medicine: Is it time to find a common language? The importance of accumulating doses across various modalities. Phys Med. 2026;145:105795.","journal-title":"Phys Med"},{"key":"7974_CR32","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","volume":"49","author":"A Sundl\u00f6v","year":"2022","unstructured":"Sundl\u00f6v A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49:3830\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7974_CR33","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s00259-025-07083-8","volume":"52","author":"R Laudicella","year":"2025","unstructured":"Laudicella R, Bauckneht M, Burger IA, Cacciola A, Fanti S, Farolfi A, Ficarra V, Iagaru A, Liberini V, Pergolizzi S, Santo G, Virgolini I, Minutoli F, Baldari S. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:2723\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7974_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cpet.2024.03.006","volume":"19","author":"H Song","year":"2024","unstructured":"Song H, Sgouros G. Alpha and beta radiation for theragnostics. PET clin. 2024;19:307\u201323.","journal-title":"PET clin"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07974-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:47Z","timestamp":1787986847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7974"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07974-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical review and approval were waived due to the nature of the study.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}